CN1832752A - 治疗淀粉样蛋白斑相关性病症的nogo－受体拮抗剂 - Google Patents

治疗淀粉样蛋白斑相关性病症的nogo－受体拮抗剂 Download PDF

Info

Publication number
CN1832752A
CN1832752A CNA2004800169194A CN200480016919A CN1832752A CN 1832752 A CN1832752 A CN 1832752A CN A2004800169194 A CNA2004800169194 A CN A2004800169194A CN 200480016919 A CN200480016919 A CN 200480016919A CN 1832752 A CN1832752 A CN 1832752A
Authority
CN
China
Prior art keywords
seq
ngr1
mammal
nogo receptor
seqid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800169194A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·M·斯特里特马特
丹尼尔·H·S·李
李维维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Biogen MA Inc
Original Assignee
Yale University
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Biogen Idec MA Inc filed Critical Yale University
Publication of CN1832752A publication Critical patent/CN1832752A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2004800169194A 2003-04-16 2004-04-16 治疗淀粉样蛋白斑相关性病症的nogo－受体拮抗剂 Pending CN1832752A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46342403P 2003-04-16 2003-04-16
US60/463,424 2003-04-16

Publications (1)

Publication Number Publication Date
CN1832752A true CN1832752A (zh) 2006-09-13

Family

ID=33310776

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800169194A Pending CN1832752A (zh) 2003-04-16 2004-04-16 治疗淀粉样蛋白斑相关性病症的nogo－受体拮抗剂

Country Status (15)

Country Link
US (1) US20070065429A1 (https=)
EP (1) EP1615654A2 (https=)
JP (1) JP2006523708A (https=)
KR (1) KR20060023959A (https=)
CN (1) CN1832752A (https=)
AU (1) AU2004231742A1 (https=)
BR (1) BRPI0409562A (https=)
CA (1) CA2522649A1 (https=)
EA (1) EA009643B1 (https=)
IS (1) IS8081A (https=)
MX (1) MXPA05011100A (https=)
NO (1) NO20055392L (https=)
RS (1) RS20050774A (https=)
WO (1) WO2004093893A2 (https=)
ZA (1) ZA200509242B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
PT1534736E (pt) * 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
CA2555018A1 (en) * 2004-01-30 2005-08-18 Biogen Idec Ma Inc. Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
US8269141B2 (en) 2004-07-13 2012-09-18 Lincoln Global, Inc. Power source for electric arc welding
US9956639B2 (en) 2005-02-07 2018-05-01 Lincoln Global, Inc Modular power source for electric ARC welding and output chopper
US9855620B2 (en) 2005-02-07 2018-01-02 Lincoln Global, Inc. Welding system and method of welding
US9647555B2 (en) 2005-04-08 2017-05-09 Lincoln Global, Inc. Chopper output stage for arc welder power source
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
EP2081429A4 (en) * 2006-08-31 2010-01-06 Biogen Idec Inc PROCESS FOR PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1999066041A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
IL150566A0 (en) * 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
NZ525422A (en) * 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
JP2005507246A (ja) * 2001-08-27 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
WO2003035687A1 (en) * 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use
PT1534736E (pt) * 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists

Also Published As

Publication number Publication date
BRPI0409562A (pt) 2006-04-18
WO2004093893A2 (en) 2004-11-04
IS8081A (is) 2005-10-21
CA2522649A1 (en) 2004-11-04
KR20060023959A (ko) 2006-03-15
JP2006523708A (ja) 2006-10-19
AU2004231742A2 (en) 2004-11-04
EA200501620A1 (ru) 2006-06-30
RS20050774A (sr) 2007-12-31
NO20055392L (no) 2005-11-15
EA009643B1 (ru) 2008-02-28
US20070065429A1 (en) 2007-03-22
MXPA05011100A (es) 2006-04-18
ZA200509242B (en) 2006-12-27
AU2004231742A1 (en) 2004-11-04
EP1615654A2 (en) 2006-01-18
WO2004093893A3 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
CN1202247C (zh) 嵌合异源多亚基粘附素
CN1264427A (zh) osteoprotegerin结合蛋白和受体
JP6277127B2 (ja) インスリン様成長因子１による細胞の活性化を阻害するための方法
CN1703426A (zh) 识别β－淀粉样肽的人源化抗体
US11285149B2 (en) Enhanced immunotherapy of cancer using targeted transcriptional modulators
CN1379815A (zh) Baff受体(bcma),一种免疫调节剂
CN1347326A (zh) Baff,其封闭剂以及它们在b细胞应答的调节中的应用
EA016193B1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их использования
KR20020053066A (ko) Ａｐｒｉｌ 수용체(ｂｃｍａ) 및 그 용도
CN1541225A (zh) 识别β淀粉样肽的人源化抗体
CN1832752A (zh) 治疗淀粉样蛋白斑相关性病症的nogo－受体拮抗剂
CN1662254A (zh) Alcam和alcam调制剂
KR20140075768A (ko) 다발성-골수종 관련 질환 치료에 사용되는 항-icam-1 항체
US7128905B2 (en) Method of treating graft versus host disease by administration of a Fas antagonist
CN1242809C (zh) T－bam(cd40l)技术在制备治疗涉及平滑肌细胞的疾病的药物中的应用
US20030026780A1 (en) Innate immunity mediated methods of treating pathological conditions
CN1890567A (zh) 血管发生抑制分子及其在癌症治疗和诊断中的用途
CN101065096A (zh) 达菲抗原趋化因子受体及其应用
CN1173735C (zh) 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用
JP2008526243A (ja) Ａｇｅｒペプチド及びその使用
CN1849139A (zh) 使用针对淀粉样β肽的抗体及其组合物治疗阿尔茨海默氏病的方法
WO2021145435A1 (ja) 認知症の予防又は治療剤
JPH11335299A (ja) 抗癌剤または放射線療法の副作用軽減剤
HK40079646A (en) Methods of use of anti-trem2 antibodies
HK40126015A (zh) 用於治疗里希特氏综合症的针对cd3和cd20的双特异性抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060913